Hansa Biopharma AB (publ) (FRA:24H)
Germany · Delayed Price · Currency is EUR | Market Cap | 304.03M +87.7% |
| Revenue (ttm) | 17.36M +4.8% |
| Net Income | -63.03M |
| EPS | -0.70 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 2.902 |
| Previous Close | 2.962 |
| Day's Range | 2.902 - 2.902 |
| 52-Week Range | 2.060 - 3.800 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 22, 2026 |
About Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune... [Read more]
Financial Performance
In 2025, Hansa Biopharma AB's revenue was 222.27 million, an increase of 29.74% compared to the previous year's 171.32 million. Losses were -534.11 million, -33.84% less than in 2024.
Financial numbers in SEK Financial StatementsNews
Hansa Biopharma AB Transcript: CMD 2026
Imlifidase demonstrated strong efficacy and safety in both clinical trials and real-world use, enabling transplants for highly sensitized patients previously considered untransplantable. U.S. launch preparations are advanced, with regulatory approval expected by year-end and early adoption anticipated in experienced centers.
Hansa Biopharma AB Transcript: Jefferies Global Healthcare Conference 2026
A novel IgG degrader platform targets highly sensitized kidney transplant patients, with imlifidase showing strong phase III results and a $1B+ U.S. market opportunity. U.S. launch preparations are advanced, with regulatory and commercial milestones set for 2024, and a robust cash position supports growth.
Hansa Biopharma AB Conference Call Transcript
Hansa Biopharma AB Conference Call Transcript
Hansa Biopharma AB Transcript: Study result
The PAES study showed that imlifidase enables highly sensitized kidney transplant patients to achieve one-year graft failure-free survival of 89.6%, with patient survival at 97.9% and a favorable safety profile. Results were consistent with prior data and support full EMA approval.
Hansa Biopharma AB Press release: Study result
Hansa Biopharma AB issued a press release on May 27, 2026, disclosing material business information to investors.
Hansa Biopharma AB Slides: Study result
Hansa Biopharma AB has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Hansa Biopharma AB: Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation
The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submissionIdefirix was generally well tolerated with a safety profile consi...
Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission Idefirix was generally well tolerated with a safety profile consiste...
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
LUND, Sweden, May 26, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that results from its US Phase 3 ConfIdeS trial in kidney transplantation have been acc...
Hansa Biopharma AB Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Imlifidase enables rapid desensitization for highly sensitized kidney transplant patients, showing strong clinical results and addressing a significant unmet need. The company monetized European rights for up to EUR 150 million to fund a robust U.S. launch and pipeline expansion, including next-gen therapies for autoimmune diseases.
Hansa Biopharma AB Transcript: Investor update
IDEFIRIX was out-licensed for €110 million upfront plus a €5 million milestone, enabling broader European reach and significant non-dilutive funding. The deal extends cash runway, supports a robust U.S. launch, and reduces European costs, with key data and regulatory milestones ahead.
Hansa Biopharma AB Press release: Investor update
Hansa Biopharma AB issued a press release on May 19, 2026, disclosing material business information to investors.
Hansa Biopharma AB Slides: Investor update
Hansa Biopharma AB has posted slides in relation to its latest quarterly earnings report, which was published on May 19, 2026.
SERB To Buy Hansa Biopharma's Idefirix Rights In Europe, MENA For EUR 115 Mln
(RTTNews) - SERB Pharmaceuticals and Hansa Biopharma AB (HNSA.ST) announced Tuesday their agreement, under which SERB will acquire exclusive rights to develop and sell Hansa's kidney transplant drug I...
Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
The agreement covers the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the MENA region Significantly enhances Hansa's financial position, ensuring a robust U.S. launc...
SERB Pharmaceuticals to acquire European and MENA rights to Idefirix (imlifidase) from Hansa Biopharma for €115 million
BRUSSELS, May 19, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals ("SERB") and Hansa Biopharma AB ("Hansa") (Nasdaq Stockholm: HNSA) today announced that they have entered into an agreement under whi...
SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million
SERB Pharmaceuticals to acquire development and commercialisation rights to Idefirix® (imlifidase) in Europe and MENA from Hansa Biopharma for €115 million
Hansa Biopharma AB Earnings Call Transcript: Q1 2026
Q1 2026 saw a 48% revenue decline year-over-year amid major organizational changes, but financial runway was extended with a $30M convertible note and key clinical/regulatory milestones are expected in 2026. Early Q2 trends show improvement, with growth anticipated in H2.
Hansa Biopharma AB Quarterly report: Q1 2026
Hansa Biopharma AB has published its Q1 2026 quarterly earnings report on April 23, 2026.
Hansa Biopharma AB Slides: Q1 2026
Hansa Biopharma AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Hansa Biopharma AB Slides: Corporate presentation
Hansa Biopharma AB has posted slides in relation to its latest quarterly earnings report, which was published on April 14, 2026.
Hansa Biopharma AB: Hansa Biopharma publishes 2025 Annual and Sustainability Reports
LUND, Sweden, March 26, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ STOCKHOLM: HNSA), today published its Annual and Sustainability Reports for 2025. Peter Nicklin, C...
Hansa Biopharma publishes 2025 Annual and Sustainability Reports
LUND, Sweden, March 26, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ STOCKHOLM: HNSA), today published its Annual and Sustainability Reports for 2025. Peter Nicklin, Chair...
Hansa Biopharma AB Slides: Corporate presentation
Hansa Biopharma AB has posted slides in relation to its latest quarterly earnings report, which was published on March 13, 2026.
Hansa Biopharma AB Transcript: Leerink Global Healthcare Conference 2026
Phase 3 data for imlifidase in kidney transplant will be presented in June, with strong trial results supporting regulatory progress and a focused U.S. launch strategy. Expansion opportunities include other organ transplants, gene therapy, and a next-gen protease for rare diseases.